PBMC samples were stained with the panels of fluorochrome-conjugated monoclonal antibodies, which are in the Supplementary Table S1 . The list of mouse anti-human antibodies included: NKG2C-FITC (4:100, clone REA205), CD3-Vioblue (0.4:100, clone BW264/56), CD56-APC-Vio770 (clone REA196), CD45-VioBlue (2:100, clone REA747), CD14-PE-Vio-770 (0.4:100, clone TÜK4), CD16-APC (3:100, clone REA423) from Miltenyi Biotec, Bergisch Gladbach, Germany; HLA-DR-PE (3:100, clone L243, Sony Biotechnology, San Jose, CA, USA), CD3-PerCP (5:100, clone HIT3a), CD3-FITC (3:100, clone FIT3a), CD45RA-APC (2:100, clone HI100), CD197-FITC (5:100, clone G043H7), KIR2DL2/L3- APC (1:100, clone DX27), NKp30-PE (3:100, clone P30-15), NKG2D-PE (3:100, clone 1D11), CD45-PerCP (2:100, clone 2D1), CD57-APC (4:100, clone HNK-1) from Sony Biotechnology, San Jose, CA, USA; CD56-APC (3:100, clone N901) from Beckman Coulter, Brea, CA, USA, PD-1-Alexa Fluor 647 (1:100, clone EH12.2H7) from BioLegend, San Diego, CA, USA.
Viability staining with SytoxBlue Dead Cell stain was performed (Invitrogen, Waltham, MA, USA). The gating strategy is presented inFigure 1 .
Viability staining with SytoxBlue Dead Cell stain was performed (Invitrogen, Waltham, MA, USA). The gating strategy is presented in